$TLCC
Twinlab Consolidated Holdings Inc Stock $tlcc

$tlcc Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000175392624000562 Filed on March 19, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$2.769M	$3.144M	$13.62M
YoY Change	-69.31%	-66.33%	-74.1%
Cost Of Revenue	$1.928M	$2.130M	$8.605M
YoY Change	-71.69%	-67.08%	-77.5%
Gross Profit	$841.0K	$1.014M	$5.012M
YoY Change	-61.98%	-64.64%	-65.06%
Gross Profit Margin	30.37%	32.25%	36.81%
Selling, General & Admin	$1.024M	$1.388M	$6.401M
YoY Change	-65.11%	-63.76%	-59.93%
% of Gross Profit	121.76%	136.88%	127.71%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$5.000K	$2.000K	$35.00K
YoY Change	-58.33%	-95.35%	-32.69%
% of Gross Profit	0.59%	0.2%	0.7%
Operating Expenses	$1.024M	$1.388M	$6.401M
YoY Change	-65.11%	-63.76%	-59.93%
Operating Profit	-$183.0K	-$374.0K	-$1.389M
YoY Change	-74.69%	-61.12%	-29.53%
Interest Expense	$1.990M	-$1.842M	$8.271M
YoY Change	-6.0%	-9.08%	4.67%
% of Operating Profit
Other Income/Expense, Net	-$1.990M	$27.00K	-$8.230M
YoY Change	-4.65%		32.19%
Pretax Income	-$2.173M	-$2.500M	-$9.619M
YoY Change	-22.67%	-24.88%	17.35%
Income Tax	$0.00	$11.00K	$43.00K
% Of Pretax Income
Net Earnings	-$2.096M	-$1.548M	-$13.71M
YoY Change	-25.41%	-53.83%	66.8%
Net Earnings / Revenue	-75.7%	-49.24%	-100.71%
Basic Earnings Per Share	-$0.01		-$0.05
Diluted Earnings Per Share	-$0.01	-$0.01	-$0.05
COMMON SHARES
Basic Shares Outstanding	259.1M shares	259.1M shares	259.1M shares
Diluted Shares Outstanding	259.1M shares		259.1M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$139.0K	$19.00K	$19.00K
YoY Change	37.62%	-97.81%	-97.81%
Cash & Equivalents	$139.0K	$19.00K
Short-Term Investments
Other Short-Term Assets	$168.0K	$194.0K	$194.0K
YoY Change	-88.52%	-74.41%	-74.41%
Inventory	$3.656M	$3.402M	$3.402M
Prepaid Expenses
Receivables	$1.071M	$2.072M	$2.072M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$5.034M	$5.687M	$5.687M
YoY Change	-55.91%	-62.43%	-62.43%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.000K	$9.000K	$1.898M
YoY Change	-95.73%	-95.21%	-56.4%
Goodwill
YoY Change
Intangibles	$120.0K	$120.0K
YoY Change	0.0%	0.0%
Long-Term Investments
YoY Change
Other Assets	$1.290M	$1.290M	$1.290M
YoY Change	-0.85%	-0.85%	-0.85%
Total Long-Term Assets	$3.166M	$3.308M	$3.308M
YoY Change	-42.13%	-42.71%	-42.71%
TOTAL ASSETS
Total Short-Term Assets	$5.034M	$5.687M	$5.687M
Total Long-Term Assets	$3.166M	$3.308M	$3.308M
Total Assets	$8.200M	$8.995M	$8.995M
YoY Change	-51.45%	-56.99%	-56.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.033M	$6.803M	$6.803M
YoY Change	-59.05%	2.75%	2.75%
Accrued Expenses	$42.45M	$43.23M	$43.23M
YoY Change	11.97%	19.16%	19.16%
Deferred Revenue	$2.047M	$2.149M
YoY Change	1.39%	13.05%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$93.30M	$93.64M	$93.64M
YoY Change	-3.19%	-3.84%	-3.84%
Total Short-Term Liabilities	$147.4M	$145.8M	$145.8M
YoY Change	4.31%	2.56%	2.56%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.960M	$2.197M	$2.197M
YoY Change	-47.61%	-45.59%	-45.59%
Total Long-Term Liabilities	$1.960M	$2.197M	$2.197M
YoY Change	-47.61%		-45.59%
TOTAL LIABILITIES
Total Short-Term Liabilities	$147.4M	$145.8M	$145.8M
Total Long-Term Liabilities	$1.960M	$2.197M	$2.197M
Total Liabilities	$149.3M	$148.0M	$148.0M
YoY Change	2.97%	1.23%	1.23%
SHAREHOLDERS EQUITY
Retained Earnings	-$372.2M	-$370.1M
YoY Change	3.62%	3.85%
Common Stock	$231.6M	$231.6M
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$500.0K	$500.0K
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	-$141.1M	-$139.0M	-$139.0M
YoY Change
Total Liabilities & Shareholders Equity	$8.200M	$8.995M	$8.995M
YoY Change	-51.45%	-56.99%	-56.99%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$2.096M	-$1.548M	-$13.71M
YoY Change	-25.41%	-53.83%	66.8%
Depreciation, Depletion And Amortization	$5.000K	$2.000K	$35.00K
YoY Change	-58.33%	-95.35%	-32.69%
Cash From Operating Activities	$20.00K	$1.680M	$2.897M
YoY Change	-91.77%	-48.12%	-167.2%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$0.00
YoY Change			-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		$0.00	$0.00
YoY Change			-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$100.0K	-1.711M	-$3.744M
YoY Change	-109.9%	-35.58%	-327.32%
NET CHANGE
Cash From Operating Activities	$20.00K	1.680M	$2.897M
Cash From Investing Activities		0.000	$0.00
Cash From Financing Activities	$100.0K	-1.711M	-$3.744M
Net Change In Cash	$120.0K	-31.00K	-$847.0K
YoY Change	-115.65%	-105.33%	-69.34%
FREE CASH FLOW
Cash From Operating Activities	$20.00K	$1.680M	$2.897M
Capital Expenditures		$0.00	$0.00
Free Cash Flow		$1.680M	$2.897M
YoY Change		-48.12%	-165.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Depreciation Depreciation	38000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8222000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001590695
CY2023	us-gaap	Discontinued Operation Gain Loss On Disposal Statement Of Income Or Comprehensive Income Extensible Enumeration DiscontinuedOperationGainLossOnDisposalStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration	http://fasb.org/us-gaap/2023#IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	000-55181
CY2023	dei	Entity Registrant Name EntityRegistrantName	Twinlab Consolidated Holdings, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3951742
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	4800 T-Rex Avenue, Suite 225
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Boca Raton
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33431
CY2023	dei	City Area Code CityAreaCode	561
CY2023	dei	Local Phone Number LocalPhoneNumber	443-4301
CY2023	dei	Security12g Title Security12gTitle	Common Stock
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	3257773000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	259092833	shares
CY2023	dei	Auditor Firm AuditorFirmId	270
CY2023	dei	Auditor Name AuditorName	Tanner LLC
CY2023	dei	Auditor Location AuditorLocation	Salt Lake City, Utah
CY2023Q4	us-gaap	Cash Cash	19000	usd
CY2022Q4	us-gaap	Cash Cash	866000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2072000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1217000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	3402000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6864000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	194000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	319000	usd
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	5872000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	5687000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	15138000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1889000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2945000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1290000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1255000	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	0	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	1435000	usd
CY2023Q4	us-gaap	Assets Assets	8995000	usd
CY2022Q4	us-gaap	Assets Assets	20912000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6803000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2487000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1426000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	844000	usd
CY2023Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4106000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1628000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	39851000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	33316000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	93637000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	97381000	usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	0	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	6530000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	145823000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	142186000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2197000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3090000	usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	0	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	947000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4037000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	148020000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	146223000	usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	393898884	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	393898884	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	394000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	394000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	231249000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	231249000	usd
CY2023Q4	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	30000	usd
CY2022Q4	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	30000	usd
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	134806051	shares
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	134806051	shares
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	500000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	500000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-370138000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-356424000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-139025000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-125311000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8995000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	20912000	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	13617000	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	17208000	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8605000	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9024000	usd
CY2023	us-gaap	Gross Profit GrossProfit	5012000	usd
CY2022	us-gaap	Gross Profit GrossProfit	8184000	usd
CY2023	us-gaap	Selling Expense SellingExpense	1161000	usd
CY2022	us-gaap	Selling Expense SellingExpense	2656000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5240000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6970000	usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	340000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-1389000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1782000	usd
CY2023	us-gaap	Interest Expense InterestExpense	8271000	usd
CY2022	us-gaap	Interest Expense InterestExpense	7902000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	41000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1676000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8230000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6226000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9619000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8008000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	43000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25000	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-9662000	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-8033000	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-4052000	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-189000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-13714000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8222000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.04
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.02
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.04
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.02
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4727000	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.01
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.01
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.01
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.01
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	259092833	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	259092833	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	259092833	shares
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-117089000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8222000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-125311000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-13714000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-139025000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-13714000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8222000	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-4052000	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-189000	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-9662000	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-8033000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	35000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	168000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	623000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	941000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	-144000	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	-565000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-350000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	245000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-492000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1674000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	23000	usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-373000	usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	usd
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	340000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	344000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1048000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3605000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3221000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-3002000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-685000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	10000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-406000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	180000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-850000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1039000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	6931000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5825000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	2899000	usd
CY2023	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-2000	usd
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	414000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	2897000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4313000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	99000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-99000	usd
CY2023	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	usd
CY2022	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-99000	usd
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	144000	usd
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	0	usd
CY2023	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-3600000	usd
CY2022	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	1647000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-3744000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1647000	usd
CY2023	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0	usd
CY2022	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3744000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1647000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-847000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2765000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3631000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	866000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	1852000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	1434000	usd
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-weight: bold; line-height: 1.2;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"><span style="font-weight: bold; line-height: inherit;">Note 1 - Nature of Business</span></span></p> <p style="margin: 0pt 0pt 0pt 27pt; font-size: 10pt; line-height: 1.2; text-indent: 0pt;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; line-height: 1.2;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"><span style="font-style: italic; line-height: inherit;">Organization</span></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; line-height: 1.2;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"> </span></p> <p style="margin: 0pt; font-size: 10pt; text-align: justify; line-height: 1.2; text-indent: 27pt;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;">Twinlab Consolidated Holdings, Inc. (the “Company”, “Twinlab,” “we,” “our” and “us”) was incorporated on October 24, 2013 under the laws of the State of Nevada as Mirror Me, Inc. On August 7, 2014, we amended our articles of incorporation and changed our name to Twinlab Consolidated Holdings, Inc.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; line-height: 1.2;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; line-height: 1.2;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"><span style="font-style: italic; line-height: inherit;">Nature of Operations</span></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; line-height: 1.2;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"> </span></p> <p style="margin: 0pt; font-size: 10pt; text-align: justify; line-height: 1.2; text-indent: 27pt;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;">We are an integrated marketer, distributor and retailer of branded nutritional supplements and other natural products sold to and through domestic health and natural food stores, mass market retailers, specialty store retailers, on-line retailers and websites. Internationally, we market and distribute branded nutritional supplements and other natural products to and through health and natural product distributors and retailers.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify; line-height: 1.2;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"> </span></p> <p style="margin: 0pt; font-size: 10pt; text-align: justify; line-height: 1.2; text-indent: 27pt;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;">Our products include vitamins, minerals, specialty supplements and sports nutrition products sold under the Twinlab<span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;">®</span> brand name, a market leader in the healthy aging and beauty from within categories sold under the Reserveage Nutrition and ResVitale® brand names; diet and energy products sold under the Metabolife<span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;">®</span> brand name; and a full line of herbal teas sold under the Alvita<span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;">®</span> brand name. To accommodate consumer preferences, our products come in various formulations and delivery forms, including capsules, tablets, softgels, chewables, liquids, sprays and powders. These products are sold primarily through health and natural food stores and on-line retailers, supermarkets, and mass-market retailers.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify; line-height: 1.2;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"> </span></p> <p style="margin: 0pt; font-size: 10pt; text-align: justify; line-height: 1.2; text-indent: 27pt;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;">We also performed services between private label distributors and contract manufacturers under the NutraScience Labs (<span style="color: #000000; font-family: 'times new roman', times; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: justify; text-indent: 36px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; float: none; display: inline !important; line-height: inherit;">“NSL”</span>) brand name. NSL facilitated the production of new supplements to market and reformulated existing products to include scientifically- backed ingredients. We provided our customers with numerous production services, including manufacturing, testing, label and packaging design, order fulfillment, and regulatory compliance. </span></p> <p style="margin: 0pt; font-size: 10pt; text-align: justify; line-height: 1.2; text-indent: 27pt;"><br/></p> <p style="margin: 0pt; font-size: 10pt; text-align: justify; line-height: 1.2; text-indent: 27pt;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;">NSL facilitated the contract manufacture of a variety of high-quality vitamin and supplement products, including but not limited to, immune support supplements, cognitive support products, prebiotics an probiotics, supplements for weight management, and sports nutrition supplements. Our role in th production of these products was to help our customers manufacture or reformulate dietary supplements for sale and distribution. We did this by working with contract manufacturers to build scientifically backed formulas for resale to our end customers. We also simplified the production process by providing quality control checks, storing inventory on site, labeling and designing finished products, and drop shipping finished products ready for sale to our end customers. We did not market these private label products, but rather sold the products to the customer, who was then responsible for the marketing, distribution, and sale to retailers or to their end customers. The services performed under NSL ceased with the abandonment of operations that began in July 2023. </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify; line-height: 1.2;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"> </span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify; line-height: 1.2;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"><span style="font-style: italic; line-height: inherit;">Going Concern</span></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify; line-height: 1.2;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"> </span></p> <p style="margin: 0pt; font-size: 10pt; text-align: justify; line-height: 1.2; text-indent: 27pt;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"><span style="line-height: inherit;">The accompanying consolidated financial statements have been prepared on a going concern basis, which assumes continuity of operations and realization of assets and liabilities in the ordinary course of business. In most periods since our formation, we have generated losses from operations. At <span>December 31, 2023</span>, we had an accumulated <span style="line-height: inherit;">defic<span style="line-height: inherit;">i<span style="line-height: inherit;">t of</span></span> $</span>370,138<span style="line-height: inherit;">. H</span>istorical losses are primarily attributable to lower than planned sales resulting from low fill rates on demand due to limitations of our working capital, delayed product introductions and postponed marketing activities, merger-related and other restructuring costs, and interest and refinancing charges associated with our debt refinancing, and impairment of our goodwill and intangible assets. Losses have been funded primarily through issuance of common stock and third-party or related party debt.</span></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify; line-height: 1.2;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"> </span></p> <p style="margin: 0pt; font-size: 10pt; text-align: justify; line-height: 1.2; text-indent: 27pt;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"><span style="line-height: inherit;">Additionally, the Company is closely monitoring the impact of the world events and wide spread health issues, or pandemics on all aspects of its business and geographies, including how it will impact its customers and business partners. While the Company did not incur significant disruptions during the year ended <span>December 31, 2023</span> from the COVID-<span>19</span> pandemic, it is unable to predict the impact that future pandemics, inflation, and other world events could have on its financial condition, results of operations and cash flows due to numerous uncertainties.</span></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify; line-height: 1.2;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"> </span></p> <p style="margin: 0pt; font-size: 10pt; text-align: justify; line-height: 1.2; text-indent: 27pt;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"><span style="line-height: inherit;">Because of our history of operating losses and significant interest expense on our debt, we have a working capital deficiency of $140,136 at <span>December 31, 2023</span>.</span><span style="line-height: inherit;"> We also have $93,637 of debt, presented in current liabilities. These continuing conditions, among others, raise substantial doubt about our ability to continue as a going concern.<br/></span></span></p> <p style="margin: 10pt 0pt 0pt; font-size: 10pt; text-align: justify; line-height: 1.2; text-indent: 27pt;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: 1.2;">Management is addressing operating issues through the following actions: focusing on growing the core business and brands; continuing emphasis on major customers and key products; reducing manufacturing and operating costs and continuing to negotiate lower prices from major suppliers. We believe that we will need additional capital to execute our business plan. If additional funding is required, there can be no assurance that sources of funding will be available when needed on acceptable terms or at all.</span></p>
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-370138000	usd
CY2023Q4	tlcc	Working Capital Deficiency WorkingCapitalDeficiency	140136000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	93637000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"><span style="font-style: italic; line-height: inherit;">Use of Estimates </span></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"> </span></p> <p style="margin: 0pt; font-size: 10pt; text-align: justify; text-indent: 27pt; line-height: 1.2;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect certain reported amounts and disclosures. Actual results could differ from those estimates. Significant management estimates include those with respect to returns and allowances, allowance for doubtful accounts, reserves for inventory obsolescence, the recoverability of long-lived assets, intangibles and goodwill.</span></p>
CY2023Q4	tlcc	Contract With Customer Liability Customer Deposits Current ContractWithCustomerLiabilityCustomerDepositsCurrent	2022000	usd
CY2022Q4	tlcc	Contract With Customer Liability Customer Deposits Current ContractWithCustomerLiabilityCustomerDepositsCurrent	1856000	usd
CY2023Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	127000	usd
CY2022Q4	us-gaap	Contract With Customer Refund Liability Current ContractWithCustomerRefundLiabilityCurrent	45000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2149000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1901000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	2036000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1348000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Accumulated Allowance For Credit Loss ContractWithCustomerAssetAccumulatedAllowanceForCreditLoss	1546000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	534000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	120000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	120000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-9662000	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-8033000	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-4052000	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-189000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-13714000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	259092833	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	259092833	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	259092833	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"><span style="font-style: italic; line-height: inherit;">Significant Concentration of Credit Risk</span></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"> </span></p> <p style="margin: 0pt; font-size: 10pt; text-align: justify; text-indent: 27pt;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;">The Company maintains its cash in bank deposit accounts which, at times, exceed federally insured limits. To date, the Company has not experienced a loss or lack of access to its invested cash; however, no assurance can be provided that access to the Company's invested cash will not be impacted by adverse conditions in the financial markets.</span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"> </span></p> <p style="margin: 0pt; font-size: 10pt; text-align: justify; text-indent: 27pt;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"><span style="line-height: inherit;">Sales to our top three customers aggregated to approximately 31% and 21% of total consolidated sales in <span>2023</span> and <span>2022</span>, respectively. Sales to one of those customers were approximately 15% and 8% of total sales in <span>2023</span> and <span>2022</span>, respectively. Accounts receivable from these customers were approximately 33% and 28% of total accounts receivable as of <span>December 31, 2023</span> and <span>2022</span>, respectively.</span></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify;"><br/></p> <p style="margin: 0pt; font-size: 10pt; text-align: justify; text-indent: 27pt;"><span style="font-family: 'times new roman', times; font-size: 10pt; line-height: inherit;"><span style="line-height: inherit;">Our two major vendors accounted for 18% and 36% of purchases for the year ended <span>December 31, 2023</span> and <span>2022</span>, respectively. A third vendor represented an additional 8% and 11% of purchases for the years ended <span>December 31, 2023</span> and <span>2022</span>, respectively.</span></span></p> <p style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: justify;"><br/></p> <p style="margin: 0pt; font-size: 10pt; text-align: justify; text-indent: 27pt; font-family: 'times new roman', times;"><span style="font-family: 'times new roman', times;">A single customer represents 3% and 2% of total accounts receivable as of <span>December 31, 2023</span> and <span>December 31, 2022</span>, respectively. This customer is a related party through a director who sits on both the Company’s board of directors and that of the customer.</span></p>
CY2022	us-gaap	Depreciation Depreciation	52000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	120000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	120000	usd
CY2023Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	10882000	usd
CY2022Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	10882000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10762000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	10762000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	120000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	116000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	93637000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	97381000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	93637000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	97381000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4500000	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2022	tlcc	Class Of Warrant Or Right Granted During Period Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightGrantedDuringPeriodNumberOfSecuritiesCalledByWarrantsOrRights	0	shares
CY2022	tlcc	Class Of Warrant Or Right Granted During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightGrantedDuringPeriodExercisePriceOfWarrantsOrRights	0
CY2022	tlcc	Class Of Warrant Or Right Cancelled During Period Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightCancelledDuringPeriodNumberOfSecuritiesCalledByWarrantsOrRights	0	shares
CY2022	tlcc	Class Of Warrant Or Right Canceled During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightCanceledDuringPeriodExercisePriceOfWarrantsOrRights	0
CY2022	tlcc	Class Of Warrant Or Right Exercised During Period Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightExercisedDuringPeriodNumberOfSecuritiesCalledByWarrantsOrRights	0	shares
CY2022	tlcc	Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights	0
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4500000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2023	tlcc	Class Of Warrant Or Right Granted During Period Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightGrantedDuringPeriodNumberOfSecuritiesCalledByWarrantsOrRights	0	shares
CY2023	tlcc	Class Of Warrant Or Right Granted During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightGrantedDuringPeriodExercisePriceOfWarrantsOrRights	0
CY2023	tlcc	Class Of Warrant Or Right Cancelled During Period Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightCancelledDuringPeriodNumberOfSecuritiesCalledByWarrantsOrRights	0	shares
CY2023	tlcc	Class Of Warrant Or Right Canceled During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightCanceledDuringPeriodExercisePriceOfWarrantsOrRights	0
CY2023	tlcc	Class Of Warrant Or Right Exercised During Period Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightExercisedDuringPeriodNumberOfSecuritiesCalledByWarrantsOrRights	0	shares
CY2023	tlcc	Class Of Warrant Or Right Exercised During Period Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightExercisedDuringPeriodExercisePriceOfWarrantsOrRights	0
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	4500000	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	7194412	shares
CY2023Q4	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	1528384	shares
CY2023Q4	us-gaap	Common Stock Share Subscribed But Unissued Subscriptions Receivable CommonStockShareSubscribedButUnissuedSubscriptionsReceivable	30000	usd
CY2023Q4	tlcc	Subscription Receivable Annual Interest Rate SubscriptionReceivableAnnualInterestRate	0.05	pure
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	43000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	25000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	43000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	25000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1177000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-900000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1036000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	416000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-2213000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	484000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	43000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2873000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1723000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	843000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	321000	usd
CY2023	tlcc	Income Tax Reconciliation Federal Net Operating Losses Expirations IncomeTaxReconciliationFederalNetOperatingLossesExpirations	4280000	usd
CY2022	tlcc	Income Tax Reconciliation Federal Net Operating Losses Expirations IncomeTaxReconciliationFederalNetOperatingLossesExpirations	0	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-2213000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	484000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	6000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies IncomeTaxReconciliationTaxContingencies	943000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	43000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	25000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	58820000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	61053000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	10546000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	9408000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	4860000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	5530000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2191000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2877000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3302000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3064000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	79719000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	81932000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	79719000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	81932000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-2213000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	484000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	0	usd
CY2023	us-gaap	Lease Cost LeaseCost	706000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	90000	usd
CY2022	us-gaap	Lease Cost LeaseCost	895000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	211000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1650000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1136000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	952000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	306000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4044000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	421000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3623000	usd
CY2023	us-gaap	Sublease Income SubleaseIncome	653000	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	1368000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.083	pure

Files In Submission

Name	View Source	Status
0001753926-24-000562-index-headers.html	Edgar Link	pending
0001753926-24-000562-index.html	Edgar Link	pending
0001753926-24-000562.txt	Edgar Link	pending
0001753926-24-000562-xbrl.zip	Edgar Link	pending
ex211_1.htm	Edgar Link	pending
ex231_2.htm	Edgar Link	pending
ex311_3.htm	Edgar Link	pending
ex321_4.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tlcc-20231231.htm	Edgar Link	pending
tlcc-20231231.xsd	Edgar Link	pending
tlcc-20231231_def.xml	Edgar Link	unprocessable
tlcc-20231231_htm.xml	Edgar Link	completed
tlcc-20231231_lab.xml	Edgar Link	unprocessable
tlcc-20231231_pre.xml	Edgar Link	unprocessable
tlcc-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TLCC
Twinlab Consolidated Holdings Inc Stock $tlcc

2024 Q1 Form 10-K Financial Statement

#000175392624000562 Filed on March 19, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TLCC Twinlab Consolidated Holdings Inc Stock $tlcc

2024 Q1 Form 10-K Financial Statement

#000175392624000562 Filed on March 19, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TLCC
Twinlab Consolidated Holdings Inc Stock $tlcc